Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Inhibikase Therapeutics sold 25 million shares of common stock to RA Capital Management via an at-the-market facility for gross proceeds of $50 million. The company expects the funds, combined with existing cash, to support operations through the topline data readout of its ongoing Phase 3 IMPROVE-PAH study of IKT-001.
Key figures
- Deal Value Usd
- 50000000
- Offering Price
- 2
- Shares Offered
- 25000000
- Drug Name
- IKT-001
- Phase Of Trial
- Phase 3
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.